From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Cap-dependentendonuclease-IN-1 is an orally active cap-dependentendonuclease inhibitor with high potency. Cap-dependentendonuclease-IN-1 can be used for the research of influenza .
Cap-dependentendonuclease-IN-12 (EXP-35) is a potent Cap-dependentendonuclease inhibitor with low cytotoxicity. Cap-dependentendonuclease-IN-12 shows inhibitory activity against H1N1 .
Cap-dependentendonuclease-IN-16 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependentendonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A) .
Cap-dependentendonuclease-IN-20 is a cap-dependentendonuclease (CEN) inhibitor. Cap-dependentendonuclease-IN-20 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 4.82 μM (CN112940009A; DSC801) .
Cap-dependentendonuclease-IN-17 is a cap-dependentendonuclease (CEN) inhibitor. Cap-dependentendonuclease-IN-17 shows antiviral activity against influenza virus A/Hanfang/359/95 (H3N2) with IC50 of 1.29 μM (CN112898346A; DSC701) .
Cap-dependentendonuclease-IN-14 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependentendonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .
Cap-dependentendonuclease-IN-15 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependentendonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1) .
Cap-dependentendonuclease-IN-26 is a cap-dependentendonuclease (CEN) inhibitor with an IC50 of 286 nM. Cap-dependentendonuclease-IN-26 shows antiviral activity against many influenza A and B strains .
Cap-dependentendonuclease-IN-19 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-19 is a spirocyclic pyridone derivative. Cap-dependentendonuclease-IN-19 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN111410661A, compound 1) .
Cap-dependentendonuclease-IN-25 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-25 is a macrocyclic pyridotriazine derivative. Cap-dependentendonuclease-IN-25 has the potential for the research of viral infections caused by viruses belonging to the Orthomyxoviridae family (extracted from patent WO2020075080A1, compound 4) .
Cap-dependentendonuclease-IN-13 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .
Cap-dependentendonuclease-IN-21 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-21 inhibits the replication of influenza virus. ap-dependentendonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
Cap-dependentendonuclease-IN-23 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-23 inhibits the replication of influenza virus. ap-dependentendonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .
Cap-dependentendonuclease-IN-8 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .
Cap-dependentendonuclease-IN-5 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .
Cap-dependentendonuclease-IN-7 is a potent inhibitor of cap-dependentendonuclease (CEN). Cap-dependentendonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependentendonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)
Cap-dependentendonuclease-IN-3 is a potent inhibitor of cap-dependentendonuclease (CEN). Not only can Cap-dependentendonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependentendonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
Cap-dependentendonuclease-IN-2 is a potent inhibitor of cap-dependentendonuclease (CEN). Not only can Cap-dependentendonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependentendonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .
Cap-dependentendonuclease-IN-9 is a potent inhibitor of cap-dependentendonuclease (CEN). Not only can Cap-dependentendonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependentendonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .
Cap-dependentendonuclease-IN-10 is a potent inhibitor of cap-dependentendonuclease (CEN). Not only can Cap-dependentendonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependentendonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .
Cap-dependentendonuclease-IN-27 (Compound 8) is an orally active potent cap-dependentendonuclease (CEN) inhibitor. Cap-dependentendonuclease-IN-27, an antiviral agent, shows activity against influenza B virus. Cap-dependentendonuclease-IN-27 has inhibitory activity against IFV A/WSN/33 (H1N1) polymerase (EC50 = 12.26 nM) .
Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependentendonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .
Baloxavir (Standard) is the analytical standard of Baloxavir. This product is intended for research and analytical applications. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependentendonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .
Influenza virus-IN-7 (Example 16) is an orally active cap-dependentendonuclease inhibitor that can be used for the research of influenza viral infectious diseases .
Baloxavir-d4 (Baloxavir acid-d4; S-033447-d4) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d4 (Baloxavir-d4 acid), derived from the proagent Baloxavir-d4 marboxil, is a first-in-class, potent and selective cap-dependentendonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d4 inhibits viral RNA transcription and replication and has potently antiviral activity .
Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependentendonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus .
Baloxavir marboxil (Standard) is the analytical standard of Baloxavir marboxil. This product is intended for research and analytical applications. Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependentendonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus .
Baloxavir-d5 is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependentendonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].
Baloxavir-d4 (Baloxavir acid-d4; S-033447-d4) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d4 (Baloxavir-d4 acid), derived from the proagent Baloxavir-d4 marboxil, is a first-in-class, potent and selective cap-dependentendonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d4 inhibits viral RNA transcription and replication and has potently antiviral activity .
Baloxavir-d5 is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependentendonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].
Inquiry Online
Your information is safe with us. * Required Fields.
